Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adia MedADIA 14 EBITDA Margin % is -74.43% as of Mar. 2026. GuruFocus rates ADIA with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 663 Healthcare Providers & Services companies, Adia Med ranks worse than 87.03% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Adia Med's EBITDA for the
three
months ended in Mar. 2026 was $-0.13 Mil. Adia Med's Revenue for the
three
months ended in Mar. 2026 was $0.18 Mil. Therefore, Adia Med's EBITDA margin for the quarter that ended in Mar. 2026 was -74.43%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Adia Med EBITDA Margin % Related Terms
Adia Med EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Adia Med's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADIA vs GBCS, CCM, CDIX: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Adia Med's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adia Med EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Adia Med's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Adia Med's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adia Med (ADIA) has a EBITDA Margin % of -74.43% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adia Med and its competitors. According to the industry distribution chart, Adia Med ranks #577 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 87%.
Is Adia Med's EBITDA Margin % too high?
Adia Med's current EBITDA Margin % is -74.43%. Based on the distribution chart, Adia Med ranks #577 out of 663 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Adia Med has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Adia Med's EBITDA Margin % compare to GBCS and CCM?
According to the Healthcare Providers & Services industry distribution chart, Adia Med ranks #577 out of 663 companies for EBITDA Margin %. This places Adia Med in the lower half of its industry. The industry median EBITDA Margin % is 10.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.19, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adia Med and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adia Med's current EBITDA Margin % is -74.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adia Med stock overvalued right now?
Adia Med (ADIA) has a current EBITDA Margin % of -74.43%. The current EBITDA Margin % is -74.43%. Adia Med's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Adia Med (ADIA), the current EBITDA Margin % is -74.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adia Nutrition Inc focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Its products and the deployment of the therapies utilizing its products address various orthopedic issues, pain management, and wound repair. In addition, its products are able to be utilized in various other therapies to address anti-aging issues and other tissue repair desires. It operates in three segments The Biolete segment comprises the sale of supplements; Adia Med performs stem cell treatments to patients; and Adia Labs procures and sells stem cell products to outside clinics or to Adia Med. It derives revenue from Sales of supplements, Medical procedures, Sales of biologics and ancillary products.
14GF Score
Get the complete analysis for ADIA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADIA has been successfully added to your 
